Attached files
| file | filename |
|---|---|
| EX-99.5 - PRESS RELEASE DATED JUNE 28, 2021 - Avalon GloboCare Corp. | ea143147ex99-5_avalonglob.htm |
| EX-99.4 - THE COMPANY'S UNAUDITED PRO FORMA CONSOLIDATED COMBINED STATEMENTS OF OPERATIONS - Avalon GloboCare Corp. | ea143147ex99-4_avalonglob.htm |
| EX-99.3 - SEN LANG'S UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE QUARTER - Avalon GloboCare Corp. | ea143147ex99-3_avalonglob.htm |
| EX-99.2 - SEN LANG'S AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER - Avalon GloboCare Corp. | ea143147ex99-2_avalonglob.htm |
| EX-10.2 - AMENDMENT NO. 1 TO SECURITIES EXCHANGE AGREEMENT, DATED JUNE 24, 2021, AMONG AVA - Avalon GloboCare Corp. | ea143147ex10-2_avalonglob.htm |
| 8-K/A - AMENDMENT NO. 1 TO FORM 8-K - Avalon GloboCare Corp. | ea143147-8ka1_avalonglob.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the inclusion by reference in the registration statements on Form S-3 (File No. 333-229118) and Form S-8 (File No. 333-251196) of Avalon GloboCare Corp. of our report dated June 24, 2021, with respect to our audits of the consolidated financial statements of Lonlon Biotech Ltd. as of December 31, 2020 and 2019 and for the years then ended, which included an explanatory paragraph as to Lonlon Biotech Ltd.’s ability to continue as a going concern, which appears in this Current Report on Form 8-K of Avalon GloboCare Corp.
/s/ Friedman LLP
New York, New York
June 25, 2021